In the current situation, it is important to halt the development of the COVID-19 pandemic, but in the future a vaccine may appear that can counteract mild or asymptomatic forms of the disease. This was announced on Wednesday, February 17, by a virologist, doctor of medical sciences, researcher at the Research Center for Epidemiology and Microbiology. Gamalei Anatoly Altshtein.
“The future, I think, will be with the creation of an effective live vaccine. But it will take years, it is impossible to quickly make a drug using this technology. This vaccine will be developed based on a variant of the virus, or several of its variants, which cause an asymptomatic infection or with mild symptoms, “Altstein told the Komsomolskaya Pravda portal.
He noted that the virus is constantly evolving, changing and adapting to different conditions favorable for reproduction.
“In nature, there remain those mutations that facilitate the multiplication of the virus, and those that“ help ”it kill people disappear. Thus, the virus evolves, changes and adapts to the conditions in which it can multiply and to the immunity that humans have, ”the scientist explained.
On February 15, Canada called the international interest in the Russian Sputnik V vaccine a serious victory for the Russian Federation. The author of the article on Rasio Canada, Tamara Alteresko, clarified that initially in a number of countries the Russian development was not accepted and they wanted to find any flaws in the drug. However, the vaccine has paid off from all angles as interest in it grows around the world, including in Europe.
According to the results of the third phase of clinical trials of this vaccine, published in February by the authoritative medical journal The Lancet, the effectiveness of the drug was 91.6% after analyzing data from more than 19 thousand volunteers. At the same time, the indicator among the group of volunteers over 60 years old was 91.8%.
The first in Russia and in the world vaccine against coronavirus “Sputnik V” was registered by the Ministry of Health of the Russian Federation in August 2020, it was developed by the Gamaleya Research Center for Electrochemistry on the studied and tested platform of human adenovirus vectors.
Up-to-date information on the situation with the coronavirus is available on the websites of stopcoronavirus.rf and access vsem.rf, as well as by the hashtag #WeVotre. Hotline phone: 8 (800) 2000-112.
